Format

Send to

Choose Destination
Anticancer Res. 2019 Jan;39(1):511-517. doi: 10.21873/anticanres.13142.

Outcomes of Localized Esophageal Squamous Cell Carcinoma Patients Treated With Definitive Concurrent Chemoradiotherapy Using Either Standard or High Radiotherapy Dose: A Retrospective Study Controlling for Organ at Risk Dose.

Author information

1
Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
2
Department of Chest Surgery, China Medical University Hospital, Taichung, Taiwan, R.O.C.
3
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, R.O.C.
4
Division of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
5
Department of Computer Science and Information Engineering, Asia University, Taichung, Taiwan, R.O.C.
6
Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan, R.O.C. d16181@gmail.com.
7
Department of Radiation Oncology, China Medical University Hsinchu Hospital, Hsinchu, Taiwan, R.O.C.

Abstract

BACKGROUND/AIM:

The optimal radiotherapy dose for localized esophageal squamous cell carcinoma (ESqCC) patients treated with definitive concurrent chemo-radiotherapy (CCRT) is debated. The aim of our study was to compare patient outcomes using either standard or high radiotherapy dose.

MATERIALS AND METHODS:

Eligible patients diagnosed between 2011 and 2015 from the cancer registry of our Institute were identified and a propensity score (PS)-matched cohort (1:1 for high vs. standard dose) was constructed to balance observable potential confounders (including organ at risk dose). The hazard ratio (HR) of death between high and standard dose was compared.

RESULTS:

Our study population included 73/36 patients before/after PS matching. The HR of death at the high dose compared to the standard dose was 0.554 (95% confidence interval (CI)=0.308-0.998, p=0.049).

CONCLUSION:

Definitive CCRT using a high radiotherapy dose showed improved survival outcomes for localized ESqCC patients compared to standard dose.

KEYWORDS:

Esophageal squamous cell carcinoma; concurrent chemoradiotherapy; radiotherapy dose

PMID:
30591503
DOI:
10.21873/anticanres.13142
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center